Fluorofenidone

• Description :

  Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) [1][2][3].

• Product Name Alternative :

  AKF-PD

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  ERK; NF-κB; TGF-beta/Smad

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/fluorofenidone.html

• Purity :

  99.78

• Solubility :

  DMSO : 140 mg/mL (ultrasonic)

• Smiles :

  O=C1C=CC(C)=CN1C2=CC=CC(F)=C2

• Molecular Formula :

  C12H10FNO

• Molecular Weight :

  203.21

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wu Y, et al. Fluorofenidone alleviates cigarette smoke exposure-induced chronic lung injury by targeting ferroptosis. Sci Rep. 2024 Dec 30;14 (1) :32149.|[2]Wang H, et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868 (12) :166556. |[3]Wang S, et al. Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression. Transl Lung Cancer Res. 2024 Nov 30;13 (11) :3175-3188.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [848353-85-5]